ARCHIVES

FDA Urges Lower Target for ESA Use; Market Could Drop By More Than Half.

This article is from The Cancer Letter archive.

Vol. 33 No. 10 | March 16, 2007

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer

September 24, 1999

Cancer survivors number 9.8 million in U.S., CDC says.

June 25, 2004

NCA Declines To Set Minimum Comp Center Bed Number

April 2, 1976

NCI Programs: Advisors Approve concept For Spiral CT Image Database Consortium

November 12, 1999

NIH Panel Outlines Strategies To Manage Adrenal Tumors.

February 22, 2002

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004